

Virginia V Ferretti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7243524/publications.pdf>

Version: 2024-02-01

99
papers

5,632
citations

172457

29
h-index

76900

74
g-index

101
all docs

101
docs citations

101
times ranked

7431
citing authors

#	ARTICLE	IF	CITATIONS
1	Nutritional parameters associated with prognosis in non-critically ill hospitalized COVID-19 patients: The NUTRI-COVID19 study. <i>Clinical Nutrition</i> , 2022, 41, 2980-2987.	5.0	13
2	Clinical, virological and immunological evolution of the olfactory and gustatory dysfunction in COVID-19. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2022, 43, 103170.	1.3	11
3	Men with COVID-19 die. Women survive. <i>Maturitas</i> , 2022, 158, 34-36.	2.4	9
4	Prospective urinary albumin/creatinine ratio for diagnosis, staging, and organ response assessment in renal AL amyloidosis: results from a large cohort of patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 386-393.	2.3	6
5	Human Cytomegalovirus-Specific T-Cell Reconstitution and Late-Onset Cytomegalovirus Infection in Hematopoietic Stem Cell Transplantation Recipients following Letermovir Prophylaxis. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 211.e1-211.e9.	1.2	18
6	Autoantibodies against type I IFNs in patients with Ph-negative myeloproliferative neoplasms. <i>Blood</i> , 2022, 139, 2716-2720.	1.4	3
7	Leptin Levels of the Perinatal Period Shape Offspring's Weight Trajectories through the First Year of Age. <i>Nutrients</i> , 2022, 14, 1451.	4.1	2
8	Early T cell reconstitution and cytokine profile may help to guide a personalized management of human cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. <i>Journal of Clinical Virology</i> , 2021, 135, 104734.	3.1	5
9	Mutational and immunogenetic landscape of HCV-associated B-cell lymphoproliferative disorders. <i>American Journal of Hematology</i> , 2021, 96, E210-E214.	4.1	7
10	Relationship between clone metrics and clinical outcome in clonal cytopenia. <i>Blood</i> , 2021, 138, 965-976.	1.4	58
11	Acquired von Willebrand syndrome in myeloproliferative neoplasms with extreme thrombocytosis. <i>Hematological Oncology</i> , 2021, 39, 589-592.	1.7	4
12	Systematic screening for SARS-CoV-2 in patients with hematological malignancies on active anticancer treatment in the outpatient setting. <i>Leukemia and Lymphoma</i> , 2021, 62, 3311-3312.	1.3	0
13	Prognostic impact of somatic mutations on time to first treatment: Results of targeted next-generation sequencing in 211 patients with early stage chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2021, 96, E404-E408.	4.1	0
14	Machine Learning-based Voice Assessment for the Detection of Positive and Recovered COVID-19 Patients. <i>Journal of Voice</i> , 2021, , .	1.5	20
15	Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection. <i>Leukemia</i> , 2020, 34, 1462-1466.	7.2	30
16	Targeted next-generation sequencing reveals molecular heterogeneity in non-chronic lymphocytic leukemia clonal B-cell lymphocytosis. <i>Hematological Oncology</i> , 2020, 38, 689-697.	1.7	7
17	Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies. <i>American Journal of Hematology</i> , 2020, 95, 1473-1478.	4.1	7
18	Circulating endothelial cells in COVID-19. <i>American Journal of Hematology</i> , 2020, 95, E187-E188.	4.1	28

#	ARTICLE	IF	CITATIONS
19	Impaired virus-specific T cell responses in patients with myeloproliferative neoplasms treated with ruxolitinib. <i>Hematological Oncology</i> , 2020, 38, 554-559.	1.7	4
20	Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network. <i>American Journal of Hematology</i> , 2019, 94, 1193-1199.	4.1	18
21	A risk-stratification model based on the initial concentration of the serum monoclonal protein and MYD88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenström macroglobulinaemia or other lymphoproliferative disorders. <i>British Journal of Haematology</i> , 2019, 187, 441-446.	2.5	13
22	Smoldering multiple myeloma: the role of different scoring systems in identifying high-risk patients in real-life practice. <i>Leukemia and Lymphoma</i> , 2019, 60, 2968-2974.	1.3	5
23	Facing erythrocytosis: Results of an international physician survey. <i>American Journal of Hematology</i> , 2019, 94, E225-E227.	4.1	10
24	Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas. <i>Oncologist</i> , 2019, 24, e720-e729.	3.7	52
25	Ruxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2019, 94, E185-E188.	4.1	26
26	Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome. <i>Leukemia</i> , 2019, 33, 2495-2505.	7.2	61
27	Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network. <i>Hematological Oncology</i> , 2019, 37, 160-167.	1.7	15
28	Evaluation of Virus-Specific T Cell Responses in Patients Affected with Myeloproliferative Neoplasms Treated with Ruxolitinib. <i>Blood</i> , 2019, 134, 1660-1660.	1.4	1
29	ICA-EMA: A Tool for Assessing Nursing Complexity of Patients with Oncohematologic Disease in an Italian Center. <i>Creative Nursing</i> , 2019, 25, 157-168.	0.5	0
30	Waldenström Macroglobulinemia in Young Patients Treated in the Modern Era: A Multi-Institutional Italian Study. <i>Blood</i> , 2019, 134, 1539-1539.	1.4	0
31	Targeted Next Generation Sequencing Reveals Molecular Heterogeneity in Non-CLL Clonal B-Cell Lymphocytosis. <i>Blood</i> , 2019, 134, 1502-1502.	1.4	0
32	Whole Body Diffusion Weighted MRI (WB DWI) for the Management of Multiple Myeloma: High Concordance between MRI Diffuse Pattern and BONE Marrow Plasma CELL Infiltration RATE. <i>Blood</i> , 2019, 134, 5495-5495.	1.4	1
33	The advantages of switch to subcutaneous bortezomib in the real life. <i>Leukemia and Lymphoma</i> , 2018, 59, 1505-1507.	1.3	2
34	The Italian Mastocytosis Registry: 6-year experience from a hospital-based registry. <i>Future Oncology</i> , 2018, 14, 2713-2723.	2.4	9
35	High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO. <i>British Journal of Haematology</i> , 2018, 182, 807-815.	2.5	19
36	Molecular remission at the end of treatment is a necessary goal for a good outcome in ELN favorable-risk acute myeloid leukemia: a real-life analysis on 201 patients by the Rete Ematologica Lombarda network. <i>Annals of Hematology</i> , 2018, 97, 2107-2115.	1.8	2

#	ARTICLE	IF	CITATIONS
37	Real-life™ study of imatinib therapy in chronic phase chronic myeloid leukemia: A novel retrospective observational longitudinal analysis. <i>Hematology</i> , 2017, 22, 1-8.	1.5	2
38	Independent prognostic impact of tumour-infiltrating macrophages in early-stage Hodgkin's lymphoma. <i>Hematological Oncology</i> , 2017, 35, 296-302.	1.7	23
39	Neurological Complications Involving the Central Nervous System After Allogeneic Hematopoietic Stem Cell Transplantation During a Period of Evolution in Transplant Modalities: A Cohort Analysis. <i>Transplantation</i> , 2017, 101, 616-623.	1.0	17
40	Clinical significance of somatic mutation in unexplained blood cytopenia. <i>Blood</i> , 2017, 129, 3371-3378.	1.4	379
41	Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System. <i>Leukemia</i> , 2017, 31, 2449-2457.	7.2	51
42	Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. <i>Haematologica</i> , 2017, 102, 2077-2085.	3.5	90
43	INTERFERON-FREE ANTIVIRAL TREATMENT IN B-CELL LYMPHOPROLIFERATIVE DISORDERS ASSOCIATED WITH CHRONIC HEPATITIS-C VIRUS INFECTION. <i>Hematological Oncology</i> , 2017, 35, 145-146.	1.7	0
44	DIRECT-ACTING ANTIVIRALS DURING OR AFTER IMMUNO-CHEMOTHERAPY IN HEPATITIS C VIRUS-ASSOCIATED DIFFUSE LARGE B-CELL LYMPHOMAS. <i>Hematological Oncology</i> , 2017, 35, 194-196.	1.7	0
45	An mHealth app counseling patients and general practitioners about Multiple Myeloma. , 2017, , .		0
46	The possible role of burden of therapy on the risk of myeloma extramedullary spread. <i>Annals of Hematology</i> , 2017, 96, 73-80.	1.8	34
47	Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria. <i>Oncotarget</i> , 2017, 8, 101735-101744.	1.8	45
48	Sequential evaluation of <i>CALR</i> mutant burden in patients with myeloproliferative neoplasms. <i>Oncotarget</i> , 2017, 8, 33416-33421.	1.8	7
49	Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. <i>Blood</i> , 2016, 128, 2527-2532.	1.4	149
50	Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2016, 34, 3627-3637.	1.6	204
51	Differential clinical effects of different mutation subtypes in <i>CALR</i> -mutant myeloproliferative neoplasms. <i>Leukemia</i> , 2016, 30, 431-438.	7.2	216
52	Somatic Mutations Are Frequently Detected in Chronic Myeloid Leukemia in Chronic Phase and Do Not Affect Response to Tyrosine-Kinase Inhibitors. <i>Blood</i> , 2016, 128, 1117-1117.	1.4	1
53	Predictive Value of Mutation Analysis in the Diagnostic Approach to Patients with Unexplained Cytopenia. <i>Blood</i> , 2016, 128, 298-298.	1.4	2
54	SRSF2 Mutations Identify a Distinct Subtype of Myeloid Neoplasm Across Myelodysplastic Syndromes and Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 4337-4337.	1.4	3

#	ARTICLE	IF	CITATIONS
55	Targeted Next Generation Sequencing Identifies Novel Genetic Mutations in Patients with Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma or IgM-Monoclonal Gammopathies of Undetermined Significance. <i>Blood</i> , 2016, 128, 2928-2928.	1.4	2
56	Impact of Switching from Intravenous to Subcutaneous Bortezomib in Real Life. Overlapping Toxicity and Efficacy in All Settings of Myeloma Patients Balancing Schedule and Way of Bortezomib Administration. <i>Blood</i> , 2016, 128, 5695-5695.	1.4	0
57	VD Versus VTD Induction: Similar Efficacy in Controlling Disease in Transplant Eligible Multiple Myeloma Patients Outside Clinical Trials. <i>Blood</i> , 2016, 128, 5711-5711.	1.4	1
58	Autologous stem cell transplantation with <i>in vivo</i> purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma. <i>American Journal of Hematology</i> , 2015, 90, 230-234.	4.1	9
59	Impact of mutational status on pregnancy outcome in patients with essential thrombocytemia. <i>Haematologica</i> , 2015, 100, e443-e445.	3.5	30
60	Influence of socio-demographic features and apolipoprotein E epsilon 4 expression on the prevalence of dementia and cognitive impairment in a population of 70-74-year olds: The InveCe.Ab study. <i>Archives of Gerontology and Geriatrics</i> , 2015, 60, 334-343.	3.0	25
61	Ambient Air Pollution and Adult Asthma Incidence in Six European Cohorts (ESCAPE). <i>Environmental Health Perspectives</i> , 2015, 123, 613-621.	6.0	197
62	Corneal sub-basal neural damage pattern in multiple myeloma patients treated with bortezomib: an <i>in vivo</i> confocal study. <i>Leukemia and Lymphoma</i> , 2015, 56, 3440-3441.	1.3	2
63	Panobinostat in combination with bortezomib and dexamethasone as induction therapy in patients with multiple myeloma, candidates for autologous transplant. <i>Leukemia and Lymphoma</i> , 2015, 56, 1901-1902.	1.3	3
64	Bone marrow assessment in asymptomatic immunoglobulin <i>M</i> monoclonal gammopathies. <i>British Journal of Haematology</i> , 2015, 168, 301-302.	2.5	9
65	The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection. <i>Haematologica</i> , 2015, 100, 246-252.	3.5	73
66	Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes. <i>Leukemia</i> , 2015, 29, 66-75.	7.2	122
67	Anti-Lymphoma Activity of Interferon-Free Antiviral Treatment in Patients with Indolent B-Cell Lymphomas Associated with Hepatitis C Virus Infection. <i>Blood</i> , 2015, 126, 3938-3938.	1.4	5
68	Real Life Analysis of the Rete Ematologica Lombarda on ELN Favorable Acute Myeloid Leukemia: The Molecular Remission Is a Necessary Goal for a Good Outcome in All Different Cytogenetic/Molecular Subgroups. <i>Blood</i> , 2015, 126, 3740-3740.	1.4	0
69	Common Variation at 6q25.3 (TULP4) Influences Risk for Arterial Thrombosis in Myeloproliferative Neoplasms. <i>Blood</i> , 2015, 126, 4088-4088.	1.4	1
70	Efficacy and Toxicity of Nucleoside Analogs in Patients with Hairy Cell Leukemia Treated Outside Clinical Trials. <i>Blood</i> , 2015, 126, 5084-5084.	1.4	0
71	Cross-sectional associations between air pollution and chronic bronchitis: an ESCAPE meta-analysis across five cohorts. <i>Thorax</i> , 2014, 69, 1005-1014.	5.6	56
72	Serum C terminal telopeptide maintains its correlation with bone disease in patients with myeloma even under treatment with bisphosphonates. <i>Leukemia and Lymphoma</i> , 2014, 55, 1397-1398.	1.3	2

#	ARTICLE	IF	CITATIONS
73	Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. <i>Blood</i> , 2014, 124, 1062-1069.	1.4	340
74	Is drop-out from obesity treatment a predictable and preventable event?. <i>Nutrition Journal</i> , 2014, 13, 13.	3.4	70
75	CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis. <i>Blood</i> , 2014, 123, 2416-2419.	1.4	66
76	JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. <i>Blood</i> , 2014, 123, 1544-1551.	1.4	507
77	Psychological care of caregivers, nurses and physicians: a study of a new approach. <i>Cancer Medicine</i> , 2014, 3, 101-110.	2.8	20
78	Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. <i>Annals of Oncology</i> , 2014, 25, 1404-1410.	1.2	133
79	Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2014, 99, 489-496.	3.5	55
80	Mutation Type As a Major Determinant of Clinical Phenotype in Myeloproliferative Neoplasms Associated with Mutant Calreticulin. <i>Blood</i> , 2014, 124, 3215-3215.	1.4	1
81	Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project. <i>Blood</i> , 2014, 124, 405-405.	1.4	47
82	Confocal Microscopy Is Useful for Detection of Bortezomib Related Neuropathy (BOR-PN) in Multiple Myeloma (MM) Patients (PTS). <i>Blood</i> , 2014, 124, 5691-5691.	1.4	0
83	High Dose Therapy and Autologous Stem Cell Transplantation in Marginal Zone Lymphoma : An EBMT-FIL-Gimeto Retrospective Study. <i>Blood</i> , 2014, 124, 2526-2526.	1.4	2
84	Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms. <i>New England Journal of Medicine</i> , 2013, 369, 2379-2390.	27.0	1,698
85	Brain aging and dementia during the transition from late adulthood to old age: design and methodology of the "Invece.Ab" population-based study. <i>BMC Geriatrics</i> , 2013, 13, 98.	2.7	39
86	Monoclonal gammopathy of undetermined significance: a new proposal of workup. <i>European Journal of Haematology</i> , 2013, 91, 356-360.	2.2	24
87	Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms. <i>Blood</i> , 2013, 121, 4388-4395.	1.4	83
88	Long Term Evaluation of the Impact of Autologous Peripheral Blood Stem Cell Transplantation in Multiple Myeloma: A Cost-Effectiveness Analysis. <i>PLoS ONE</i> , 2013, 8, e75047.	2.5	11
89	High Prevalence Of Extramedullary Relapse In Patients With Multiple Myeloma Treated With Novel Biological Agents. <i>Blood</i> , 2013, 122, 1896-1896.	1.4	1
90	Non-Hodgkin's Lymphomas Associated With Positive Hepatitis-C Virus Infection: A Prospective Multicentric Observational Study On Behalf Of The "Rete Ematologica Lombarda/Hematology Network Of Lombardia Region". <i>Blood</i> , 2013, 122, 3003-3003.	1.4	1

#	ARTICLE	IF	CITATIONS
91	JAK2 (V617F)-Positive Essential Thrombocythemia and Polycythemia Vera Are Different Expressions Of a Genotypic/Phenotypic Continuum. <i>Blood</i> , 2013, 122, 1592-1592.	1.4	1
92	Epidemiology and Geographical Variation of Myasthenia Gravis in the Province of Pavia, Italy. <i>Neuroepidemiology</i> , 2012, 38, 100-105.	2.3	23
93	Epidemiology of multiple sclerosis in south-western Sardinia. <i>Multiple Sclerosis Journal</i> , 2011, 17, 1282-1289.	3.0	66
94	Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas. <i>American Journal of Hematology</i> , 2010, 85, 46-50.	4.1	52
95	Assessment of bone marrow involvement in non-Hodgkin's lymphomas: comparison between histology and flow cytometry. <i>European Journal of Haematology</i> , 2010, 85, 405-415.	2.2	30
96	Validation of follicular lymphoma international prognostic index 2 (FLIPI2) score in an independent series of follicular lymphoma patients. <i>British Journal of Haematology</i> , 2010, 149, 455-457.	2.5	36
97	Nonexpanded Mesenchymal Stem Cells for Regenerative Medicine: Yield in Stromal Vascular Fraction from Adipose Tissues. <i>Tissue Engineering - Part C: Methods</i> , 2010, 16, 1515-1521.	2.1	99
98	Stereotyped Patterns of HCDR3 Sequences in Splenic Marginal Zone B-Cell Lymphoma (SMZL): SMZL-Biased Subsets Are Associated with a Worse Outcome.. <i>Blood</i> , 2009, 114, 760-760.	1.4	0
99	Haematological malignancies in relatives of patients affected with myeloproliferative neoplasms. <i>EJHaem</i> , 0, , .	1.0	0